159 related articles for article (PubMed ID: 36807624)
1. LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.
Jennings D; Huntwork-Rodriguez S; Vissers MFJM; Daryani VM; Diaz D; Goo MS; Chen JJ; Maciuca R; Fraser K; Mabrouk OS; van de Wetering de Rooij J; Heuberger JAAC; Groeneveld GJ; Borin MT; Cruz-Herranz A; Graham D; Scearce-Levie K; De Vicente J; Henry AG; Chin P; Ho C; Troyer MD
Mov Disord; 2023 Mar; 38(3):386-398. PubMed ID: 36807624
[TBL] [Abstract][Full Text] [Related]
2. A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls.
Vissers MFJM; Troyer MD; Thijssen E; Pereira DR; Heuberger JAAC; Groeneveld GJ; Huntwork-Rodriguez S
Clin Transl Sci; 2023 Aug; 16(8):1408-1420. PubMed ID: 37177855
[TBL] [Abstract][Full Text] [Related]
3. Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
Bright JM; Carlisle HJ; Toda AMA; Murphy M; Molitor TP; Wren P; Andruska KM; Liu E; Barlow C
Mov Disord; 2021 Jun; 36(6):1362-1371. PubMed ID: 33836114
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.
Jennings D; Huntwork-Rodriguez S; Henry AG; Sasaki JC; Meisner R; Diaz D; Solanoy H; Wang X; Negrou E; Bondar VV; Ghosh R; Maloney MT; Propson NE; Zhu Y; Maciuca RD; Harris L; Kay A; LeWitt P; King TA; Kern D; Ellenbogen A; Goodman I; Siderowf A; Aldred J; Omidvar O; Masoud ST; Davis SS; Arguello A; Estrada AA; de Vicente J; Sweeney ZK; Astarita G; Borin MT; Wong BK; Wong H; Nguyen H; Scearce-Levie K; Ho C; Troyer MD
Sci Transl Med; 2022 Jun; 14(648):eabj2658. PubMed ID: 35675433
[TBL] [Abstract][Full Text] [Related]
5. Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker.
Perera G; Ranola M; Rowe DB; Halliday GM; Dzamko N
Sci Rep; 2016 Aug; 6():31391. PubMed ID: 27503089
[TBL] [Abstract][Full Text] [Related]
6. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients.
Atashrazm F; Hammond D; Perera G; Bolliger MF; Matar E; Halliday GM; Schüle B; Lewis SJG; Nichols RJ; Dzamko N
Mov Disord; 2019 Mar; 34(3):406-415. PubMed ID: 30597610
[TBL] [Abstract][Full Text] [Related]
7. Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development.
Alcalay RN; Hsieh F; Tengstrand E; Padmanabhan S; Baptista M; Kehoe C; Narayan S; Boehme AK; Merchant K
Mov Disord; 2020 Jan; 35(1):134-141. PubMed ID: 31505072
[TBL] [Abstract][Full Text] [Related]
8. Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease.
Garrido A; Santamaría E; Fernández-Irigoyen J; Soto M; Simonet C; Fernández M; Obiang D; Tolosa E; Martí MJ; Padmanabhan S; Malagelada C; Ezquerra M; Fernández-Santiago R
Mov Disord; 2022 May; 37(5):1004-1015. PubMed ID: 35049090
[TBL] [Abstract][Full Text] [Related]
9. Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients.
Fernández B; Lara Ordóñez AJ; Fdez E; Mutez E; Comptdaer T; Leghay C; Kreisler A; Simonin C; Vandewynckel L; Defebvre L; Destée A; Bleuse S; Taymans JM; Chartier-Harlin MC; Hilfiker S
Biochem J; 2019 Oct; 476(19):2797-2813. PubMed ID: 31527116
[TBL] [Abstract][Full Text] [Related]
10. LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes.
Mancini A; Stoops E; Demeyer L; Bellomo G; Paolini Paoletti F; Gaetani L; Di Filippo M; Parnetti L
Mov Disord; 2023 Apr; 38(4):682-688. PubMed ID: 36808643
[TBL] [Abstract][Full Text] [Related]
11. Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils.
Fan Y; Howden AJM; Sarhan AR; Lis P; Ito G; Martinez TN; Brockmann K; Gasser T; Alessi DR; Sammler EM
Biochem J; 2018 Jan; 475(1):23-44. PubMed ID: 29127255
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
[TBL] [Abstract][Full Text] [Related]
13. An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts.
Padmanabhan S; Lanz TA; Gorman D; Wolfe M; Joyce A; Cabrera C; Lawrence-Henderson R; Levers N; Joshi N; Ma TC; Liong C; Narayan S; Alcalay RN; Hutten SJ; Baptista MAS; Merchant K
J Parkinsons Dis; 2020; 10(2):623-629. PubMed ID: 32007961
[TBL] [Abstract][Full Text] [Related]
14. A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator.
den Heijer JM; Kruithof AC; Moerland M; Walker M; Dudgeon L; Justman C; Solomini I; Splitalny L; Leymarie N; Khatri K; Cullen VC; Hilt DC; Groeneveld GJ; Lansbury P
Mov Disord; 2023 Jul; 38(7):1197-1208. PubMed ID: 37195859
[TBL] [Abstract][Full Text] [Related]
15. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
[TBL] [Abstract][Full Text] [Related]
16. Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells.
Thirstrup K; Dächsel JC; Oppermann FS; Williamson DS; Smith GP; Fog K; Christensen KV
Sci Rep; 2017 Aug; 7(1):10300. PubMed ID: 28860483
[TBL] [Abstract][Full Text] [Related]
17. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
18. Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients.
Dzamko N; Chua G; Ranola M; Rowe DB; Halliday GM
J Parkinsons Dis; 2013; 3(2):145-52. PubMed ID: 23938344
[TBL] [Abstract][Full Text] [Related]
19. Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target.
Chen J; Chen Y; Pu J
Eur Neurol; 2018; 79(5-6):256-265. PubMed ID: 29705795
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease.
Gonzalez-Hunt CP; Thacker EA; Toste CM; Boularand S; Deprets S; Dubois L; Sanders LH
Sci Rep; 2020 Oct; 10(1):17293. PubMed ID: 33057100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
